Status:
COMPLETED
Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment
Lead Sponsor:
University of Freiburg
Conditions:
Acute Myeloid Leukemia, in Relapse
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
In this study, the outcomes of relapsed AML patients receiving DLIs and Bicanorm (Sodium bicarbonate) were analyzed including T cell metabolism and immune phenotype.
Detailed Description
Acute myeloid leukemia (AML) patients suffering from relapse after allogeneic hematopoietic cell transplantation (allo-HCT) have a poor survival outcome. Donor lymphocyte infusions (DLIs) to induce gr...
Eligibility Criteria
Inclusion
- confirmed AML relapse after allo-HCT
- patients receiving DLIs
- age ≥ 18 years
- written informed consent
- ability to understand the nature of the study and the study related procedures and to comply with them
Exclusion
- age \< 18 years
- lack of informed consent
Key Trial Info
Start Date :
February 25 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 18 2020
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04321161
Start Date
February 25 2020
End Date
March 18 2020
Last Update
March 25 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Center University of Freiburg
Freiburg im Breisgau, Baden-Wurttemberg, Germany, 79106